Assessing treatment-time interaction in clinical trials with time to event data: A meta-analysis of hypertension trials

Statistics in Medicine

Volumn 17, Issue 24, 1998, Pages 2883-2903

  Boutitie, F ^a   Gueyffier, F ^a   Pocock, S J ^b   Boissel, J P ^a  

^a UNIVERSITÉ LYON 1   (France)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

CALCULATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; HISTOGRAM; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; META ANALYSIS; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL MODEL; SURVIVAL RATE;

HUMANS; HYPERTENSION; META-ANALYSIS; MODELS, STATISTICAL; POISSON DISTRIBUTION; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0032583382     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0258(19981230)17:24<2883::AID-SIM900>3.0.CO;2-L     Document Type: Conference Paper

References (35)

1. Stewart, L. A. and Parmar, M. K. B. 'Meta-analysis of the literature or of individual patient data: is there a difference?', Lancet, 341, 418-422 (1993).
2. Hess, K. R. 'Graphical methods for assessing violations of the proportional hazards assumption in Cox regression', Statistics in Medicine, 14, 1707-1723 (1995).
3. Kay, R. 'Goodness of fit methods for the proportional hazards regression model: a review', Revue d'Epidemiologie et de Santé Publique, 32, 185-198 (1984).
4. Cox, D. R. 'Regression models and life-tables (with discussion)', Journal of the Royal Statistical Society, 34, 187-220 (1972).
5. Gueyffier, F., Boutitie, F., Boissel, J. P., Coope, J., Cutler, J., Ekbom, T., Fagard, R., Friedman, L., Perry, H. M., Pocock, S. J., et al. 'INDANA: a meta-analysis on individual patient data in hypertension. Protocol and preliminary results', Thérapie, 50, 353-362 (1995).
6. Coope, J. and Warrender, T. S. 'Randomised trial of treatment of hypertension in elderly patients in primary care', British Medical Journal, 293, 1145-1151 (1986).
7. Amery, A., Brixko, P. and Clement, D. 'Mortality and morbidity results from the European working party on high blood pressure in the elderly', Lancet, i, 1349-1354 (1985).
8. Hypertension Detection and Follow-up Program Cooperative Group. 'Five-year findings of the Hypertension Detection and Follow-up Program: I: Reduction in mortality of persons with high blood pressure, including mild hypertension', Journal of the American Medical Association, 242, 2562-2571 (1979).
9. Medical Research Council Working Party. 'MRC trial of treatment of mild hypertension: principal results', British Medical Journal, 291, 97-104 (1985).
10. Medical Research Council Working Party. 'MRC trial of treatment of hypertension in older adults: principal results', British Medical Journal, 304, 405-412 (1992).
11. SHEP Cooperative Research Study Group. 'Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP)', Journal of American Medical Association, 265, 3255-3264 (1991).
12. Multiple Risk Factor Intervention Trial Research Group. 'Multiple Risk Factor Intervention Trial: risk factor changes and mortality results', Journal of the American Medical Association, 248, 1465-1477 (1982).
13. Australian National Blood Pressure Management Committee. 'The Australian therapeutic trial in mild hypertension', Lancet, i, 1261-1267 (1980).
14. Veterans Administration/National Heart, Lung, and Blood Institute Study Group for Cooperative Studies in Antihypertensive Therapy: Mild Hypertension (Perry HM). 'Treatment of mild hypertension: preliminary results of a two-year feasibility trial', Circulation Research, 40 (Suppl 1), 180-187 (1997).
15. Dalhöf, B., Lindholm, L. H., Hansson, L., Schersten, B., Ekbom, T. and Wester, P. O. 'Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension), Lancet, 338, 1281-1285 (1991).
16. Hess, K. R. 'Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions', Statistics in Medicine, 13, 1045-1062 (1994).
17. Thall, P. F. and Lachin, J. M. 'Assessment of stratum-covariate interactions in Cox's proportional hazards regression model', Statistics in Medicine, 5, 73-83 (1986).
18. Kalbfleisch, J. D. and Prentice, R. L. The Statistical Analysis of Failure Time Data, Wiley, 1980.
19. Anderson, J. A. and Senthilselvan, A. 'A two-step regression model for hazard functions', Applied Statistics, 31, 44-51 (1982).
20. Gore, S. M., Pocock, S. J. and Kerr, G. R. 'Regression models and non-proportional hazards in the analysis of breast cancer survival', Applied Statistics, 33, 176-195 (1984).
21. Gray, R. J. 'Some diagnostic methods for Cox regression models through hazard smoothing', Biometrics, 46, 93-102 (1990).
22. Durrleman, S. and Simon, R. 'Flexible regression models with cubic splines', Statistics in Medicine, 8, 551-561 (1989).
23. Simon, R. 'Use of regression models: statistical aspects', in Buyse, M. E., Staquet, M. J. and Sylvester, R. J. (ed.), Cancer Clinical Trials Methods and Practice, Oxford University Press, Oxford, 1984, pp. 444-466.
24. O'Quigley, J. and Pessione, F. 'Score tests for homogeneity of regression effect in the proportional hazards model', Biometrics, 45, 135-144 (1989).
25. SAS Institute Inc. SAS Supplemental Library User's Guide 1980 Edition, SAS Institute Inc. Cary, N.C., 1980.
26. Dabrowska, D. M., Doksum, K. A., Feduska, N. J., Husing, R. and Neville, P. 'Methods for comparing cumulative hazard functions in a semi-proportional hazard model', Statistics in Medicine, 11, 1465-1476 (1992).
27. Breslow, N. 'Discussion on "Regression models and life tables" by D. R. Cox', Journal of the Royal Statistical Society, Series B, 34, 216-217 (1972).
28. Collins, R., Peto, R. and MacMahon, S. 'Blood pressure, stroke, and coronary heart disease. Part 2', Lancet, 335, 827-838 (1990).
29. Smith, P. G. and Day, N. E. 'The design of case control studies: influence of confounding and interaction effects', International Journal of Epidemiology, 13, 356-365 (1984).
30. Thompson, S. G. 'Why sources of heterogeneity in meta-analysis should be investigated?', British Medical Journal, 309, 1351-1355 (1994).
31. Chastang, C., Byar, D. and Piantadosi, S. 'A quantitative study of the bias in estimating the treatment effect caused by omitting a balanced covariate in survival models', Statistics in Medicine, 7, 1243-1255 (1988).
32. Schumacher, M., Olschewski, M. and Schmoor, C. 'The impact of heterogeneity on the comparison of survival times', Statistics in Medicine, 6, 773-784 (1987).
33. Antiplatelet Trialist's Collaboration. 'Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patietns', British Medical Journal, 308, 81-106 (1994).
34. Law, M. R., Wald, N. J. and Thompson, S. G. 'By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?', British Medical Journal, 308, 367-372 (1994).
35. The Scandinavian Simvastatin Survival Study Group. 'Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease "The Scandinavian Simvastatin Survival Study"', Lancet, 344, 1383-1389 (1994).